1. Search Result
Search Result
Results for "

viral replication complex

" in MedChemExpress (MCE) Product Catalog:

22

Inhibitors & Agonists

1

Fluorescent Dye

1

Natural
Products

Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-153810

    JNJ-1802

    Virus Protease Flavivirus Dengue Virus Infection
    Mosnodenvir (JNJ-1802) is an orally active pan serotype dengue virus (DENV) inhibitor, with EC50 values ranging from 0.057 to 11 nM for four dengue virus (DENV) serotypes. Mosnodenvir blocks viral replication by inhibiting the formation of complexes between two viral proteins, nonstructural protein 3 (NS3) and NS4B, thereby preventing the formation of new viral RNA. Mosnodenvir exhibits picomolar to nanomolar antiviral activity in vitro and has antiviral efficacy in mice and non-human primates .
    Mosnodenvir
  • HY-N7922
    Urolithin M5
    1 Publications Verification

    Decarboxyellagic acid

    Influenza Virus p38 MAPK EGFR Akt Reactive Oxygen Species (ROS) Apoptosis Infection Neurological Disease
    Urolithin M5 (Decarboxyellagic acid) is an orally active influenza virus neuraminidase inhibitor and neuroprotective agent, with IC50 values of 174.8 μM (HK68), 191.5 μM (pdm09), 243.2 μM (WSN) and 257.1 μM (PR8) against four influenza virus neuraminidases, respectively. Urolithin M5 inhibits viral neuraminidase activity, thereby blocking influenza virus replication (including oseltamivir (HY-13317)-resistant strains), protecting infected mammals from death and improving pulmonary edema. Urolithin M5 forms a hydrogen-bond stabilized complex with IGF1R, and binds to MAPK14, AKT1, NFKB1 and EGFR. Urolithin M5 reduces reactive oxygen species production, inhibits neuronal apoptosis, restores mitochondrial transmembrane potential, and promotes neurite outgrowth of damaged neuronal cells. Urolithin M5 can be used in research related to influenza virus infection and Alzheimer's disease .
    Urolithin M5
  • HY-103713
    Seclidemstat
    Maximum Cited Publications
    11 Publications Verification

    SP-2577

    Histone Demethylase Cancer
    Seclidemstat is a potent noncompetitive and reversible KDM1A (LSD1) inhibitor (Ki=31 nM, IC50=13 nM). Seclidemstat promotes antitumor immunity in switch/sucrose nonfermentable (SWI/SNF) complex mutated ovarian cancer, as well as inhibit virus production, viral DNA replication, and late gene expression. Seclidemstat can be used for the research of Ewing Sarcoma .
    Seclidemstat
  • HY-139602
    (+)-JNJ-A07
    2 Publications Verification

    Flavivirus Dengue Virus Virus Protease Infection
    (+)-JNJ-A07 is a highly potent, orally active pan-serotype dengue virus inhibitor targeting the NS3-NS4B interaction. (+)-JNJ-A07 exerts nanomolar to picomolar activity against a panel of 21 clinical isolates. (+)-JNJ-A07 has a favourable pharmacokinetic profile that results in outstanding efficacy against dengue virus infection in mouse infection models .
    (+)-JNJ-A07
  • HY-173679

    PROTACs PARP Interleukin Related STAT Integrin HSV VSV Infection Cancer
    RBN012811 is a highly selective PROTAC-based PARP14 degrader. RBN012811 forms a ternary complex with cereblon by binding to the NAD + site of PARP14, and mediates the specific degradation of PARP14 via the ubiquitin-proteasome pathway (IC50=10 nM). RBN012811 effectively depletes endogenous PARP14 in various cell lines and primary human macrophages, thereby downregulating IL-10 production and IFN-β mRNA levels, increasing phosphorylated STAT1 levels to enhance inflammatory signaling, and inhibiting interferon-induced ADPr condensate formation. RBN012811 also modulates viral replication, exhibiting increased HSV1 replication while reducing VSV replication. RBN012811 has important application value in research related to cancer and viral infections .
    RBN012811
  • HY-103713A
    Seclidemstat mesylate
    Maximum Cited Publications
    11 Publications Verification

    SP-2577 mesylate

    Histone Demethylase Cancer
    Seclidemstat (SP-2577) mesylate is a potent noncompetitive and reversible KDM1A (LSD1) inhibitor (Ki=31 nM, IC50=13 nM). Seclidemstat mesylate promotes antitumor immunity in switch/sucrose nonfermentable (SWI/SNF) complex mutated ovarian cancer, as well as inhibit virus production, viral DNA replication, and late gene expression. Seclidemstat mesylate can be used for the research of Ewing Sarcoma .
    Seclidemstat mesylate
  • HY-149648

    RSV DNA/RNA Synthesis Infection
    JNJ-8003 is a potent and orally active non-nucleoside RSV polymerase inhibitor with an IC50 of 0.29 nM. JNJ-8003 targets the L protein polymerase complex of RSV (IC50 = 0.67 nM), and blocks the transcription and replication of the viral genome by inhibiting the activity of RNA-dependent RNA polymerase (RdRp). JNJ-8003 displays subnanomolar activity in vitro as well as prominent efficacy in mice and a neonatal lamb models. JNJ-8003 can be used for the study of respiratory syncytial virus (RSV) .
    JNJ-8003
  • HY-163529

    HSV Cytochrome P450 Infection
    HN0037 is a selective, orally active Helicase-primase inhibitor. HN0037 is mainly metabolized by CYP3A4. HN0037 inhibits HSV replication by targeting the viral helicase-primase complex, which consists of three proteins encoded by UL5 (helicase), UL52 (primase), and UL8 (scaffold protein that promotes primer synthesis) .
    HN0037
  • HY-170524

    SARS-CoV DNA Methyltransferase Cytochrome P450 Infection
    TDI-015051 is a highly selective, orally active antiviral agent that targets the coronavirus NSP14 guanine-N7 methyltransferase. TDI-015051 binds to substrates in a non-competitive manner and forms a stable ternary complex, precisely blocking the capping and methylation processes of viral mRNA. TDI-015051 potently inhibits a variety of coronaviruses (including SARS-CoV-2 and MERS). By impairing viral replication and translation and inducing a moderate type I interferon-mediated immune response, it significantly reduces pulmonary viral load and exhibits a synergistic effect with Nirmatrelvir (HY-138687). In addition, TDI-015051 does not inhibit non-coronavirus methyltransferases, and the drug-resistant mutations it induces impair viral fitness, demonstrating excellent antiviral properties and safety. TDI-015051 can be used for research on COVID-19 and the replication mechanism of coronaviruses .The IC50 values of TDI-015051 against SARS-CoV-2, α-hCoV-NL63, α-hCoV-229E, β-hCoV-MERS are 0.15 nM, 1.7 nM, 2.6 nM and 3.6 nM, respectively, and the Ka value against SARS-CoV-2 is 0.061 nM .
    TDI-015051
  • HY-176433

    Flavivirus Infection
    NSC-323241 is a potent STT3A-mediated mega protein complex assembly inhibitor. NSC-323241 disrupts he endoplasmic reticulum (ER) mega complex nucleated by STT3A during dengue virus (DENV) and Zika virus (ZIKV) infection. NSC-323241 targets the binding of STT3A subcomplex with viral nonstructural proteins (e.g., NS2B, NS3) and host translocon proteins, disrupting the formation of viral replication microenvironment. NSC-323241 is promising for research of flavivirus infection, such as dengue fever and Zika virus .
    NSC-323241
  • HY-174252

    DNA/RNA Synthesis HSV Infection
    HSV-1/HSV-2-IN-3 inhibits the herpes-simplex-virus (HSV) helicase-primase complex, blocking the coordinated DNA-unwinding and primer-synthesis steps required for viral genome replication. HSV-1/HSV-2-IN-3 exhibits an EC50 of 7.0 nM against HSV-2 in a gD-immunofluorescence cell assay containing 2 % FBS and 57.5 nM when 10 % human serum is present. HSV-1/HSV-2-IN-3 achieves an EC50 of 1.1 nM in a qPCR replication assay. HSV-1/HSV-2-IN-3 shows strong selectivity over human carbonic-anhydrase off-targets (IC50 ≈ 2.9 µM for hCA II and > 35 µM for hCA I). HSV-1/HSV-2-IN-3 can be studied in anti-HSV research .
    HSV-1/HSV-2-IN-3
  • HY-158028

    Influenza Virus Infection
    PAN endonuclease-IN-2 (compound T-31) is a PAN endonuclease inhibitor (IC50: 0.15 μM) and antiviral agent with broad-spectrum anti- Influenza activity. PAN is the N-terminal PA subunit of the polymerase-RNA complex and the dependent endonuclease (CEN) active site. PAN initiates RNA replication by promoting cleavage of the RNA strand and allowing the polymerase to begin synthesizing new RNA molecules. PAN endonuclease-IN-2 targets both the influenza HA and RdRp complexes, thereby interfering with viral entry into host cells and viral replication .
    PAN endonuclease-IN-2
  • HY-163529A

    HSV Infection
    (S)-HN0037 is the (S)-isomer of HN0037 (HY-163529), a selective and orally active helicase-primase inhibitor that inhibits HSV replication by targeting the viral helicase-primase enzyme complex .
    (S)-HN0037
  • HY-163546

    HSV Infection
    HSV-1-IN-1 (compound 1b) is a drug candidate for herpes simplex virus HSV-1(IC50=0.5 nM) and HSV-2(IC50=16 nM) infection. HSV-1-IN-1 inhibits the helicase-primase complex to prevent viral replication, thereby inhibiting HSV infection .
    HSV-1-IN-1
  • HY-174431

    Endonuclease Influenza Virus Infection
    PAN endonuclease-IN-3 is a potent PAN endonuclease inhibitor that against influenza virus polymerase complexes with an IC50 of 17.4 nM. PAN endonuclease-IN-3 demonstrates potent inhibitory activities against PAN endonuclease. PAN endonuclease-IN-3 demonstrates robust antiviral activities against multiple current and different influenza virus strains while showing minimal cytotoxicity in MDCK cells. PAN endonuclease-IN-3 significantly suppresses viral replication in an A/WSN/33 infected mouse model.
    PAN endonuclease-IN-3
  • HY-D2946

    BC-TMR

    Fluorescent Dye Infection
    CLIP-TMR (BC-TMR) is a TMR-labeled CLIP tag fluorescent probe. CLIP-TMR combines the high specificity recognition ability of the CLIP-tag and the excellent optical performance of the TMR fluorophore, and can be used for the specific labeling and visualization of the HCV NS5A protein .
    CLIP-TMR
  • HY-W1135843

    Arenavirus Infection
    ARN-75039 is an orally active arenavirus inhibitor. ARN-75039 binds to sites on the GP2 subunit of the mammarenavirus glycoprotein complex, stabilizes prefusion conformation, and blocks viral entry and endosomal membrane fusion to inhibit viral replication and spread. ARN-75039 can be used for the research of lassa fever, arenaviral hemorrhagic fever, and lethal Junín virus infection .
    ARN-75039
  • HY-182317

    Drug Isomer Dengue Virus Infection
    (+)-Mosnodenvir is an isomer of Mosnodenvir (HY-153810). Mosnodenvir (JNJ-1802) is an orally active pan serotype dengue virus (DENV) inhibitor, with EC50 values ranging from 0.057 to 11 nM for four dengue virus (DENV) serotypes. Mosnodenvir blocks viral replication by inhibiting the formation of complexes between two viral proteins, nonstructural protein 3 (NS3) and NS4B, thereby preventing the formation of new viral RNA. Mosnodenvir exhibits picomolar to nanomolar antiviral activity in vitro and has antiviral efficacy in mice and non-human primates .
    (+)-Mosnodenvir
  • HY-182566

    HIV Infection
    ITI-367 is a HIV-1 inhibitor that targets the nuclear localization signal 1 (NLS-1) of HIV-1 matrix protein and the interaction between HIV-1 pre-integration complex (PIC) and importin-β. ITI-367 inhibits HIV-1 replication at the pre-integration stage, reduces the formation of 2-LTR circles, and sequesters viral DNA in the cytoplasm. ITI-367 can be used for the research of HIV infection .
    ITI-367
  • HY-103713AR

    SP-2577 mesylate (Standard)

    Reference Standards Histone Demethylase Cancer
    Seclidemstat mesylate (Standard) is the analytical standard of Seclidemstat mesylate (HY-103713A). This product is intended for research and analytical applications. Seclidemstat (SP-2577) mesylate is a potent noncompetitive and reversible KDM1A (LSD1) inhibitor (Ki=31 nM, IC50=13 nM). Seclidemstat mesylate promotes antitumor immunity in switch/sucrose nonfermentable (SWI/SNF) complex mutated ovarian cancer, as well as inhibit virus production, viral DNA replication, and late gene expression. Seclidemstat mesylate can be used for the research of Ewing Sarcoma .
    Seclidemstat mesylate (Standard)
  • HY-103713R

    SP-2577 (Standard)

    Reference Standards Histone Demethylase Cancer
    Seclidemstat (Standard) is the analytical standard of Seclidemstat (HY-103713). This product is intended for research and analytical applications. Seclidemstat is a potent noncompetitive and reversible KDM1A (LSD1) inhibitor (Ki=31 nM, IC50=13 nM). Seclidemstat promotes antitumor immunity in switch/sucrose nonfermentable (SWI/SNF) complex mutated ovarian cancer, as well as inhibit virus production, viral DNA replication, and late gene expression. Seclidemstat can be used for the research of Ewing Sarcoma .
    Seclidemstat (Standard)
  • HY-180269

    Influenza Virus DNA/RNA Synthesis Infection
    Anti-Influenza agent 10 (Compound 41) is an influenza A virus RNA-dependent RNA polymerase (RdRp) inhibitor. Anti-Influenza agent 10 exhibits potent antiviral activity against A/PR/8/34(H1N1) with an IC50 of 0.29μM and a KD of 4.11 μM. Anti-Influenza agent 10 can inhibit the assembly of the viral RdRp complex by disrupting the protein interaction between PA and PB1 subunits, thereby blocking the transcription and replication of the viral genome. Anti-Influenza agent 10 shows significant broad-spectrum effects on multiple influenza virus strains, such as H3N2, H3N8 and H9N2 with IC50 values of 3.96, 1.91 and 1.45 μM. Anti-Influenza agent 10 can be used for the research of influenza A Virus Infection .
    Anti-Influenza agent 10

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

 

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

 

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: